Study Groups of Project 9: Chronic myeloproliferative diseases (CMPD)

Created by: Reiter (Project 9) , generated 2006/05/04, last changed: 2006/05/10


Name of the study group	European LeukemiaNet Eosinophilia Study Group
Disease(s)	Eosinophilia associated chronic myeloproliferative disorders (e. g. idiopathic hypereosinophilic syndrome, chronic eosinophilic leukemia, atypical chronic myeloid leukemia with eosinophilia, systemic mastocytosis with eosinophilia)
Leader(s) of the study group	Prof. J. Apperley Imperial College School of Medicine Hammersmith Hospital London, UK j.apperley@ic.ac.uk Prof. G. Martinelli Institute of Hematology and Medical Oncology "L. and A. Seràgnoli. University of Bologna, Via Massarenti, 9-40138 Bologna, Italy. gmartino@kaiser.alma.unibo.it Dr. A. Reiter III. Medizinische Universitätsklinik, Klinikum Mannheim der Universität Heidelberg, Wiesbadener Str. 7-11, 68305 Mannheim. Germany andreas.reiter@med3.ma.uni-heidelberg.de Prof. N. C. P. Cross Wessex Regional Genetics Laboratories, Salisbury, U.K. & Human Genetics Research Division, University of Southampton School of Medicine, Southampton, UK ncpc@soton.ac.uk Prof. Saglio Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, 10043 Orbassano-Turin, Italy. giuseppe.saglio@unito.it Dr. J. Cools Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium jan.cools@med.kuleuven.ac.be Dr. D. Cilloni Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, 10043 Orbassano-Turin, Italy. daniela.cilloni@unito.it Prof. C. Preudhomme Laboratoire d'Hématologie A, Hôpital Calmette-CHU of Lille, France; Unité INSERM-U524-Lille cpreudhomme@chru-lille.fr Dr. A. Sureda Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, St Antoni Maria Claret, 167, 08025 Barcelona, Spain. asureda@hsp.santpau.es
Website	http://www.leukemia-net.org/
Studies	Italy Imatinib in HES (Principal investigator: Prof. G. Martinelli, Bologna, see above) Germany Evaluation of the efficacy, safety and tolerability of imatinib mesylate (Glivec ) in patients with idiopathic hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL) and systemic mastocytosis with eosinophilia (SME). (Phase II). (Principal investigator: PD Dr. A. Reiter, Mannheim, see above) UK Contact person: Prof. J. Apperley, London, see above (for shortprotocols, see studies)
Contact persons	See above
Diagnostic Labs	Prof. Dr. N.C.P. Cross Wessex Regional Cytogenetics Centre, Salisbury, United Kingdom. ncpc@soton.ac.uk PD Dr. A. Reiter III. Medizinische Universitätsklinik, Klinikum Mannheim der Universität Heidelberg, Wiesbadener Str. 7-11, 68305 Mannheim, Germany andreas.reiter@med3.ma.uni-heidelberg.de Prof. Dr. Saglio Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, 10043 Turin, Italy. saglio@csi.it Dr. J. Cools Flanders Interuniversity Institute for Biotechnology, Leuven, Belgium jan.cools@med.kuleuven.ac.be Prof. Dr. C. Preudhomme Laboratoire d'Hématologie A, Hôpital Calmette-CHU of Lille, France; Unité INSERM-U524-Lille cpreudhomme@chru-lille.fr

European Treatment and Outcome Study

EUTOS for CML is a unique collaboration between the European LeukemiaNet and Novartis Oncology in Europe